60 Degrees Pharmaceuticals Announces Potential Market Size For ARAKODA, Plans To File NDA In 2026

(RTTNews) - 60 Degrees Pharmaceuticals, Inc. (SXTP), Tuesday announced the potential maximum size of the commercial market for ARAKODA, projecting it to be 380,000 patients/$245,000,000 in sales annually, with a cumulative total addressable market of 1.17 million patients/$1.1 billion through patent expiration in 2035.

Notably, the total addressable market for ARAKODA for treatment of babesiosis, a serious and debilitating emerging tick-borne illness, was based on data from a 6,000 nationwide patient survey and a quantitative research study involving 300 healthcare professionals.

The company added that it intends to file for New Drug Application in 2026.

In the pre-market hours, SXTP is trading at $2.55, up 17.78 percent on the Nasdaq.